Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer’s disease

[1]  John F. Ouyang,et al.  Transcriptional signature in microglia associated with Aβ plaque phagocytosis , 2021, Nature Communications.

[2]  William T. Ralvenius,et al.  APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia , 2021, Science Translational Medicine.

[3]  J. Cummings,et al.  AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery , 2021, Alzheimer's Research & Therapy.

[4]  J. Trojanowski,et al.  Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative , 2020, Molecular Psychiatry.

[5]  R. Nussinov,et al.  Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing , 2020, Medicinal research reviews.

[6]  T. Strovas,et al.  Synergistic toxicity between tau and amyloid drives neuronal dysfunction and neurodegeneration in transgenic C. elegans. , 2020, Human molecular genetics.

[7]  Rosemary J. Jackson,et al.  Amyloid Beta and Tau Cooperate to Cause Reversible Behavioral and Transcriptional Deficits in a Model of Alzheimer’s Disease , 2019, Cell reports.

[8]  A. Hingorani,et al.  Lipid lowering and Alzheimer disease risk: A mendelian randomization study , 2019, Annals of neurology.

[9]  L. Tan,et al.  Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies , 2019, Ageing Research Reviews.

[10]  D. Holtzman,et al.  Alzheimer Disease: An Update on Pathobiology and Treatment Strategies , 2019, Cell.

[11]  Mendelian randomization indicates that TNF is not causally associated with Alzheimer's disease , 2019, Neurobiology of Aging.

[12]  R. Nussinov,et al.  A Systems Pharmacology Approach Uncovers Wogonoside as an Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling. , 2019, Cell chemical biology.

[13]  Hinrich W. H. Göhlmann,et al.  A genetics-led approach defines the drug target landscape of 30 immune-related traits , 2019, Nature Genetics.

[14]  J. Sutcliffe,et al.  A Bayesian framework that integrates multi-omics data and gene networks predicts risk genes from schizophrenia GWAS data , 2019, Nature Neuroscience.

[15]  S. Davis,et al.  Mechanisms Associated with Type 2 Diabetes as a Risk Factor for Alzheimer-Related Pathology , 2019, Molecular Neurobiology.

[16]  Nick C. Fox,et al.  Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. , 2018, Nature Medicine.

[17]  Benjamin A. Logsdon,et al.  Genome-wide RNAseq study of the molecular mechanisms underlying microglia activation in response to pathological tau perturbation in the rTg4510 tau transgenic animal model , 2018, Molecular Neurodegeneration.

[18]  F. Tanaka,et al.  Microglia in Alzheimer's Disease: Risk Factors and Inflammation , 2018, Front. Neurol..

[19]  C. Gaiteri,et al.  The Molecular and Neuropathological Consequences of Genetic Risk for Alzheimer's Dementia , 2018, Front. Neurosci..

[20]  J. Klappenbach,et al.  Human Alzheimer’s disease gene expression signatures and immune profile in APP mouse models: a discrete transcriptomic view of Aβ plaque pathology , 2018, Journal of Neuroinflammation.

[21]  S. Makin,et al.  The amyloid hypothesis on trial , 2018, Nature.

[22]  E. Guney,et al.  Proximal Pathway Enrichment Analysis for Targeting Comorbid Diseases via Network Endopharmacology , 2018, Pharmaceuticals.

[23]  Y. Son,et al.  Sildenafil protects neuronal cells from mitochondrial toxicity induced by β-amyloid peptide via ATP-sensitive K+ channels. , 2018, Biochemical and biophysical research communications.

[24]  D. Llewellyn,et al.  Individual and Area-Based Socioeconomic Factors Associated With Dementia Incidence in England , 2018, JAMA psychiatry.

[25]  Lindsay A. Farrer,et al.  Genome-wide association study of Alzheimer's disease endophenotypes at prediagnosis stages , 2018, Alzheimer's & Dementia.

[26]  Julia M. Barbarino,et al.  PharmGKB: A worldwide resource for pharmacogenomic information , 2018, Wiley interdisciplinary reviews. Systems biology and medicine.

[27]  Alasdair J. G. Gray,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY , 2017, Nucleic Acids Res..

[28]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[29]  D. Brat,et al.  (−)-P7C3-S243 Protects a Rat Model of Alzheimer’s Disease From Neuropsychiatric Deficits and Neurodegeneration Without Altering Amyloid Deposition or Reactive Glia , 2017, Biological Psychiatry.

[30]  Aidan Budd,et al.  SignaLink: Multilayered Regulatory Networks. , 2018, Methods in molecular biology.

[31]  Dohyun Han,et al.  Molecular and functional signatures in a novel Alzheimer’s disease mouse model assessed by quantitative proteomics , 2018, Molecular Neurodegeneration.

[32]  J. Götz,et al.  Tau-based therapies in neurodegeneration: opportunities and challenges , 2017, Nature Reviews Drug Discovery.

[33]  David S. Park,et al.  β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease , 2017, Science.

[34]  Daniel B. McClatchy,et al.  Amyloid accumulation drives proteome-wide alterations in mouse models of Alzheimer’s disease like pathology , 2017, bioRxiv.

[35]  Pedro Rosa-Neto,et al.  Synergistic interaction between amyloid and tau predicts the progression to dementia , 2017, Alzheimer's & Dementia.

[36]  Ingvild Saltvedt,et al.  Association between blood pressure and Alzheimer disease measured up to 27 years prior to diagnosis: the HUNT Study , 2017, Alzheimer's Research & Therapy.

[37]  P. Stenson,et al.  The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies , 2017, Human Genetics.

[38]  Gautier Koscielny,et al.  Open Targets: a platform for therapeutic target identification and validation , 2016, Nucleic Acids Res..

[39]  George Papadatos,et al.  The ChEMBL database in 2017 , 2016, Nucleic Acids Res..

[40]  Doron Lancet,et al.  MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search , 2016, Nucleic Acids Res..

[41]  Núria Queralt-Rosinach,et al.  DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants , 2016, Nucleic Acids Res..

[42]  Jos Prickaerts,et al.  From Age-Related Cognitive Decline to Alzheimer's Disease: A Translational Overview of the Potential Role for Phosphodiesterases. , 2017, Advances in neurobiology.

[43]  Martin Ringwald,et al.  Mouse Genome Informatics (MGI): Resources for Mining Mouse Genetic, Genomic, and Biological Data in Support of Primary and Translational Research. , 2017, Methods in molecular biology.

[44]  A. Barabasi,et al.  Tissue Specificity of Human Disease Module , 2016, Scientific Reports.

[45]  Albert-László Barabási,et al.  Endophenotype Network Models: Common Core of Complex Diseases , 2016, Scientific Reports.

[46]  Alzheimer’s Association,et al.  2016 Alzheimer's disease facts and figures , 2016, Alzheimer's & Dementia.

[47]  Karl Broich,et al.  Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. , 2016, JAMA neurology.

[48]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[49]  A. Barabasi,et al.  Network-based in silico drug efficacy screening , 2016, Nature Communications.

[50]  Michael K. Gilson,et al.  BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology , 2015, Nucleic Acids Res..

[51]  J. Claassen.  New cardiovascular targets to prevent late onset Alzheimer disease. , 2015, European journal of pharmacology.

[52]  Mulin Jun Li,et al.  Nature Genetics Advance Online Publication a N a Ly S I S the Support of Human Genetic Evidence for Approved Drug Indications , 2022 .

[53]  A. Barabasi,et al.  Uncovering disease-disease relationships through the incomplete interactome , 2015, Science.

[54]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[55]  Bridget E. Begg,et al.  A Proteome-Scale Map of the Human Interactome Network , 2014, Cell.

[56]  J. Cummings,et al.  Alzheimer’s disease drug-development pipeline: few candidates, frequent failures , 2014, Alzheimer's Research & Therapy.

[57]  Ying Xu,et al.  Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice , 2013, Behavioural Brain Research.

[58]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[59]  J. Lanciego,et al.  Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD , 2013, Neuropharmacology.

[60]  Jie Shen,et al.  admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET Properties , 2012, J. Chem. Inf. Model..

[61]  L. Mucke,et al.  Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.

[62]  R. Franco,et al.  Sildenafil restores cognitive function without affecting β‐amyloid burden in a mouse model of Alzheimer's disease , 2011, British journal of pharmacology.

[63]  P. Hof,et al.  Carvedilol as a potential novel agent for the treatment of Alzheimer's disease , 2011, Neurobiology of Aging.

[64]  K. Pritchard,et al.  Inhibition of CDKS by roscovitine suppressed LPS-induced *NO production through inhibiting NFkappaB activation and BH4 biosynthesis in macrophages. , 2009, American journal of physiology. Cell physiology.

[65]  R. Jope,et al.  Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. , 2009, Cellular signalling.

[66]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[67]  L. Ferrucci,et al.  Comorbidity : The Ultimate Geriatric Syndrome Review Article Methodology , Design , and Analytic Techniques to Address Measurement of Comorbid Disease , 2007 .

[68]  H. Ghofrani,et al.  Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond , 2006, Nature Reviews Drug Discovery.

[69]  S. L. Wong,et al.  Towards a proteome-scale map of the human protein–protein interaction network , 2005, Nature.

[70]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[71]  Y. Benjamini,et al.  THE CONTROL OF THE FALSE DISCOVERY RATE IN MULTIPLE TESTING UNDER DEPENDENCY , 2001 .

[72]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.